Abstract Library

#4498 Quality of life outcome after each cycle in NET patients receiving peptide receptor radionuclide therapy (PRRT)

Introduction: Quality of Life (QoL) Questionnaire GI NET21 was developed specifically for neuroendocrine tumours (NET). A significant proportion of all patients with GEP-NETs will ultimately present with a wide variety of NET-related symptoms such as skin flushing, diarrhoea and pain as well as disease related worries that can reduce QoL. Peptide receptor radionuclide therapy (PRRT) is an established treatment in NETs and has been shown to extend survival. However, QoL data post PRRT is still somewhat limited.

Conference:

Presenting Author: Vito I

Authors: Vito I, Santillan N, Davis N, Navalkissoor S,

Keywords: Lu-177-DOTATATE, PRRT, Quality of Life,

#3003 The Proinflammatory Molecule, VAP-1, Is Enriched in the Stroma of Midgut NETs and Plaques of Carcinoid Heart Disease Valves

Introduction: Vascular adhesion protein-1 (VAP-1) is a novel driver of tissue inflammation and fibrosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Shah T, Sagar V, Neil D, Liu B, Barriuso J,

Keywords: carcinoid, GEP-NET, VAP-1, ECM, tumour stroma, biomarker,

#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)

Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rodriguez-Freixinos V

Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,

Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,

#2698 Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ghaleb N

Authors: Ghaleb N, Dick R, Heraghty N, Zwane-Allen P, Vadrucci M,

Keywords: Nuclear Medicine, Hybrid Imaging, Relapse Therapy, PRRT, Survival, Toxicity,

#1629 To Treat or Watch? Identifying Drivers of Decisions for Patients with GEP-NET Using Reflective Multi-Criteria Decision Analysis

Introduction: Somatostatin analogs (SSAs) or watchful-waiting are recommended for unresectable, well- or moderately-differentiated non-functioning GEP-NET.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Goetghebeur M, Samaha D, Khoury H, O'Neil W, Lavoie L,

Keywords: MCDA, decision making, GEP-NET, EVIDEM,